Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

McLaren Applied Technologies and the University of Oxford have announced a new partnership that aims to improve the efficiency of patient care and optimise the treatment journey for serious conditions. 

The agreement, which was signed today at McLaren’s headquarters in Woking, will focus on three core areas: 

  • Surgical simulations and outcomes monitoring – creating programmes which advance surgeon training methods, improve patient preparation for surgery and enhance the monitoring of surgery effectiveness.
  • Clinical care optimisation – improving patient care journeys in key need areas, while reducing complications and length of stay in hospital.
  • Facilities optimisation - reviewing the management and allocation of critical medical resources (such as emergency departments) and clinical staff in order to optimise efficiency and availability.

Read more (McLaren Applied Technologies website)

Similar stories

Study reveals ‘stop-eating’ response to DNA damage

A new study from the MRC Weatherall Institute of Molecular Medicine sheds light on the mechanism by which DNA damage suppresses appetite, a finding with implications for understanding the appetite lowering side-effects of chemotherapy.

Fiona Powrie appointed new Deputy Chair of Wellcome’s Board of Governors

Fiona Powrie, Director of the Kennedy Institute of Rheumatology at the University of Oxford has been selected as the next Deputy Chair of Wellcome’s Board of Governors.

World’s first cancer prevention trial to test diabetes drug in patients with high-risk genetic condition

Oxford researchers will lead a £2m national cancer prevention trial to assess the benefit a diabetes drug has in patients with Li Fraumeni Syndrome (LFS), a genetic condition that impacts 1 in 20,000 people worldwide and puts them at a 70-90% lifetime risk of cancer.

One high altitude explorer acknowledges another

NASA Astronaut and Physiologist Dr Jessica Meir unveils The Physiological Society blue plaque in honour of fellow pioneering Physiologist and Scientific Explorer Mabel FitzGerald.

Oxford-led research maps milestone stage of human development for the first time

Scientists have shed light on an important stage of early embryonic development that has never been fully mapped out in humans before.